Nascent Biotech

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Our mission is to become a market leader in biotechnologies by consistently developing, manufacturing, and delivering high-quality and cost-effective products for research and clinical applications.

Our vision is to become a symbol of excellence in the future of biotechnologies by striving to continuously push boundaries to make life easier, healthier and more enjoyable.

Nascent Biotech has been recognized by leading organizations and magazines for its innovation, customer service and quality products, and has been nominated for the X Award for Excellence in Biotechnologies for 2020.